melanoma

[Merck & Co., Inc.] Merck announced that the Phase III KEYNOTE-716 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resected stage IIB and IIC melanoma met its key secondary endpoint of distant metastasis-free survival at a pre-specified interim analysis.

[Evaxion Biotech A/S] Evaxion Biotech A/S finalized recruitment for Phase I/IIa clinical trial of EVX-02 in adjuvant melanoma patients.

[International Journal of Oncology] Researchers determined the effects of antagonism of the transient receptor potential melastatin‑2 ion channel in primary human malignant melanoma cells.

[Journal of Natural Products] An in-house library of 2576 plant extracts was screened on two melanoma cell lines with different oncogenic mutations leading to pathological ERK/AKT activity.

[Expert Review of Molecular Diagnostics] Investigators summarize the state of the art on circulating microRNAs detectable in skin cancer patients including all the studies that performed microRNA identification and quantification in the circulation using appropriate sample size and statistics and provide detailed methodology.

[Journal of Trace Elements in Medicine and Biology] Scientists investigated whether boric acid could be a new candidate molecule that could be used in the treatment of colon cancer.